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Original Article
Treatment of Vesicovaginal Fistulas With
Autologous Cell Injections—A Randomized
Study in an Animal Model
Marianne S. Jepsen, MD1,2, Jeeva Sellathurai, PhD, MSc2,3,
Alessandro Conti, MD1,4, Henrik D. Schrøder, Dr. Med.2,3,
and Lars Lund, Dr. Med., D.M.Sci.1,2
Abstract
Purpose: To evaluate the effect of autologous satellite cell and smooth muscle cell transplantation on vesicovaginal fistulas in
a randomized controlled study by comparing the proportion of fistula closure and tissue composition between the 2 groups.
Materials and Methods: Eight pigs underwent surgery to establish an experimental induced fistula. One pig was excluded due
to insufficient weight gain. Seven pigs were randomized to receive either an injection of satellite cells and smooth muscle cells or
no treatment. Cells were isolated from abdominal skeletal muscle and bladder smooth muscle, cultured in vitro, and marked with
bromodeoxyuridine. Cell purity, growth kinetics, and differentiation potential were determined. Cells were injected around the
fistula using a cystoscope. Five weeks after the injection of cells, the fistula area was examined macroscopically and histologically.
Results: The isolated satellite cell population consisted of 76.6% neural cell adhesion molecule positive cell and the
smooth muscle cell population of 88.6% a-smooth muscle actin positive cells. All pigs had a persisting fistula before
treatment. One of the 4 vesicovaginal fistulas was closed 5 weeks after injection of satellite cells and smooth muscle cells
compared to none in the control group. No histological differences in the tissue composition between the 2 groups were
observed and no bromodeoxyuridine-labeled cells were detected around the fistula tissue in the histological examination.
Conclusion: We established an animal model with a persisting clinical and histological confirmed vesicovaginal fistula. The study indi-
cated that there might be an effect on vesicovaginal fistula closure using an injection of satellite cells/smooth muscle cells and alginate gel.
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Abbreviations
ASCs, adipose-derived stem cells; ASMA, a-smooth muscle actin; BrdU, bromodeoxyuridine; DM, differentiation medium;
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protein; GM, growth medium; IM, intramuscular; IV, intravenous; NCAM, neural cell adhesion molecule; MSCs, bone marrow-
derived mesenchymal stromal cells; PBS, phosphate-buffered saline; PSA, penicillin, streptomycin, and Fungizone antimycotic; SCs,
satellite cells; SMCs, smooth muscle cells; VVF, vesicovaginal fistula
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Introduction
Vesicovaginal fistula (VVF) is defined as an abnormal anato-
mical passage between the urinary bladder and the vagina. It
results in continuous urine leakage accompanied by several
complications, for example, recurrent urinary tract infections,
vaginal fungal infections, skin infections and irritations, and
rarely pelvic pain.1 Women affected by VVF also having
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psychological and social problems such as depression and iso-
lation from society due to an unpleasant odor.2
Although rare, VVF in the developed countries is reported
as a complication to surgery of benign indication and as part of
pelvic malignancy.3-7 It is seen as a complication to hysterect-
omy of malign indication, the risk being the highest in the
treatment of cervical cancer.3 The VVFs are also seen as
a consequence of radiotherapy for pelvic tumors.3,5,7
The VVFs are usually treated surgically, either with a vagi-
nal or with an abdominal approach.1 Success rate is the highest
in primary fistula repair ranging from 71.2% to 95.7%, depend-
ing on fistula size, involvement of urethra or the bladder neck
and the number of fistulas.4,5,8 It is indicated that the success
rate might be lower, when looking only at VVF in relation to
malignancy.4,6 Complications associated with surgical repair
are bleeding, infection, and damage to other structures.4 Recur-
rence is seen in 6.4%.4
A cystoscopic injection of stem cells and tissue-specific
cells such as smooth muscle cells (SMCs) is a potential mini-
mal invasive treatment of VVF, hence it improves success rate
of VVF closure and patient comfort, leading to faster recovery.
Muscle-specific stem cells, also called satellite cells (SCs), can
be isolated and cultured from a muscle sample. Satellite cells
are able to survive, proliferate, and differentiate in vivo when
transplanted into both human and animal tissues.9 Skeletal
myoblasts have shown a positive effect on both heart function
in an animal model with heart failure, probably due to struc-
tural changes, less interstitial fibrosis, and a different composi-
tion of collagen fibers.10 Hypothetically the combination of
SCs and SMCs might be able to restore tissue with the same
dynamic contractility as normal bladder wall, thus achieving
fistula closure without affecting bladder function.
Injection of cells has resulted in poor outcome due to a
large and rapid loss of cells and reduced migration.11 Hydro-
gels are cell delivery vehicles that increase in vitro viability,
proliferation, and differentiation potential of myoblast.12
Increased survival, migration, and distribution of cells in vivo
are also observed thus improving the efficacy of stem cell
transplantation.13,14
The purpose of this randomized controlled study was to
establish an animal model with a histologically verified VVF
and a method for cell implantation in the treatment of VVF.
Materials and Methods
This randomized study was conducted at a fully licensed
Danish animal research laboratory and performed in agreement
with The Danish Animal Research law. Approval was obtained
from the Danish Animal Experiments Inspectorate (ref. no.
2015-15-0201-00470). Since this is a pilot project, it was only
necessary with a minimum number of pigs. Based on the results
from the underlying project by Lindberg et al,15 where 50% of
the pigs developed persistent fistulas, it was decided to use 4
pigs in each group to ensure pigs with fistulas in each group.
Eight female 12-week-old Landrace/Yorkshire pigs with an
initial mean weight of 42.8 + 0.71 kg were housed at The
Biomedical Laboratory (University of Southern Denmark,
Denmark).
They were placed 2 and 2 in 2  2.8 m pens on a safe vinyl
floor with JELUXYl Premium Bedding (JELU-WERK,
Germany) and straw. The room temperature was 21C + 1C,
dark/light cycle was 12 h/12 h, and the air humidity was 30% to
50%. The pigs had free access to clean tab water and were fed
with Svin Enhed Classic (DLG, Denmark). Before the beginning
of each procedure, animals were sedated with intramuscular
(IM) metetomidin (0.05 mg/kg), midazolam (0.25 mg/kg), and
atropine (0.05 mg/kg). After sedation, the animals received intra-
venous (IV) propofol (2.5-3.75 mg/kg), IV buprenorphine (0.03
mg/kg), and IM ampicillin (15 mg/kg). They were endotrache-
ally intubated and connected to a respirator. During the proce-
dures, anesthesia was maintained with either isoflurane (2.2%)
or continuous IV propofol (7.7-9.2 mg/kg/h). After the proce-
dure, the animals received percutaneous fentanyl (1.2 mg/24 h)
for 3 days and IM ampicillin (16.8 mg/kg) for 5 days.
The VVFwas created according to Lindberg et al.15 A vertical
laparotomywas performed from below the umbilicus to the sym-
physis including a peritoneal opening and through the peritoneum
to reach the bladder surface. A vertical incision was made in the
bladder from the apex toward the neck on the ventral and lower
surface with a length of proximal 7 cm. A cuffed tracheal tube
(size 6.0, TeleflexMedical, Ireland) was placed in the vagina and
palpated through the bladder and vaginalwall. The tubewas fixed
with Babcock forceps, and an incision was made at the tip of the
tracheal tube.Anabsorbable continuousMonocryl3/0wasplaced
around the incision, thereby creating the fistula. The cuff was
filled with sterile saline, and the tube was secured to the bladder
wall using 2 absorbable Vicryl 3.0 sutures. The tube was cut to a
length of 16 cm. The bladder was closed in 2 layers, and the
peritoneum, abdominal muscle, and cutis were closed according
to normal practice with Vicryl 2.0 sutures. Samples for cell iso-
lation were taken from the bladder and the abdominal skeletal
muscle. The surgical procedure was performed by 2 urologists.
Four weeks postoperatively, a cystoscopy using a flexible
cystoscope (CYF-4; Olympus, Ballerup, Denmark) was per-
formed to examine the fistula in vivo.
SCs and SMCswere isolated from the abdominal skeletal mus-
cles and bladder tissue, respectively. Cells were handled as
described by Sellathurai et al.16 Samples were trimmed of visible
connective tissue and adipose tissue, minced and digested in 3.5%
collagenase type II (Worthington Biochemical Corporation, New
Jersey) for 60 minutes at 37C. Subsequently, the suspension was
centrifuged at 1000 rpm for 10 minutes. The pellet was suspended
in growth medium (GM) containing Dulbecco’s Modified Eagle
Medium (DMEM) with 10% fetal bovine serum (FBS) and 1%
penicillin, streptomycin, and Fungizone antimycotic (PSA) and
filtered through 100 mm and 40 mm nylon mesh. The suspension
was centrifuged at 1000 rpm for 10 minutes. The remaining cell
pellet was suspended in GM, transferred to culture flasks
(225 cm2), and cultured inGMat 37C and 5%CO2. Satellite cells
were cultured in flasks coated with extracellular matrix gel (ECM;
Sigma-Aldrich, Denmark). The upscaled cells (15-25 106) were
stored at 80C until further use.
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SCs and SMCs were characterized in terms of purity and
growth kinetics. In addition, SCs differentiation potential was
evaluated.
SCs and SMCs were seeded at a density of 6000 cells/cm2 in
12-well plates containing coverslips coated with ECM and cul-
tured in GM followed by harvest after 48 hours. For differentia-
tion, SCs were grown in proliferation medium consisting of GM
with 10% horse serum. Cells were changed to GM at 80% con-
fluence, and 20 hours later to differentiation medium (DM) con-
taining DMEM with 5% FBS, 1 mM insulin (Life Technologies,
Denmark), 1mMcytosine arabinoside (Sigma-Aldrich,Denmark),
and 1% PSA. Coverslips were harvested after 17 days in DM.
Growth kinetics of SCs and SMCs were evaluated by seed-
ing cells at a density of 3500 cells/cm2 in 6-well plates in GM.
Cells were detached with trypsin/EDTA and counted every day
for 6 days using a Bu¨rker hemocytometer. The counting was
made in triplicates.
Four weeks postoperatively, the pigs with persisting VVF
were randomized to either injection of hydrogel encapsulated
SCs/SMCs or no treatment. Randomization was blinded using
GraphPad QuickCalcs.17
Satellite cells and SMCs were thawed and cultured in GM
containing 0.01 mM bromodeoxyuridine (BrdU; Sigma-
Aldrich, Denmark) for 4 days before injection.
A small number of cells were seeded on coverslips and
harvested 2 days later for immunocytochemistry.
Before injections of SCs/SMCs were performed, a flexible
cystoscope was used to examine the fistula in vivo and place a
wire guide (Roadrunner Hydrophilic PC Wire Guide 0.035
in/145 cm; Cook Medical, Bloomington, Indiana, USA) in the
urethra. A cystoscopic injection needle (5 Fr  8 mm; Cook
Medical) was inserted through the operative channel of a rigid
cystoscope (22.5 Fr and 12 optics, Olympus, Ballerup, Den-
mark), and a total of 5 mL sterile 1% sodium alginate gel (diluted
in phosphate-buffered saline [PBS]; 0.1 mg/mL PBS; PRO-
NOVA UP LVM; BioPolymer AS, Norway), containing 18 
106 SCs and 4.5 106 SMCs, was injected in 4 places around the
fistula. Subsequently, a new injection needlewas inserted and 0.3
mL diluted calcium chloride (0.01 mg/mL PBS) was injected at
the same sites to induce cross-linking in the gel and formation of a
fixed gel structure. In order to immobilize the bladder by con-
tinuous bladder drainage to reduce tension of fistula area, an
endotracheal tube with cuff (size 4.0 mm, Unomedical, Den-
mark) was inserted in the bladder, cut and secured to the vaginal
wall using absorbable Vicryl 1.0.
Five weeks after the pigs received an injection of
SCs/SMCs, the animals were euthanized with pentobarbital
(34 mg/kg), and the fistula area was removed and examined
macroscopically.
The fistula area was fixed in 4% formaldehyde and embedded
in paraffin. Sections of 3 mmwere cut and stained with hematox-
ylin and erosin and Sirius red according to standard procedures.
Cells cultured on coverslips were stained immunohisto-
chemically for neural cell adhesion molecule (NCAM),
a-smoothmuscle actin (ASMA), desmin, and BrdU, and sections
from fistula area were stained for BrdU according to Table 1.
The ratios of NCAM-positive SCs and ASMA-positive
SMCs were determined to assess the purity of the cell cultures.
The ratio of BrdU positive cells were determined to assess the
labeling efficiency in cells prior to transplantation.
Table 1. Overview of the Used Antibodies for Immunocytochemistry and Immunohistochemistry.a
Antibodies Clone Dilution Source Fixation Detection Systemb Positive Control Negative Controlc
Immunocytochemistry
NCAM ERIC-1 1:200 NMd Acetone, 10 minutes PowerVisionþe Human fetal muscle Porcine SCs
Desmin D33 1:200 Dakoe Acetone, 10 minutes PowerVisionþ Human fetal muscle Differentiated
porcine myoblast
ASMA 14A 1:200 Dako Acetone, 10 minutes EnVisionþe Normal porcine bladder Porcine SMCs
BrdU Bu20a 1:20 Dako 96% ethanol, 30 minutes
! 2 M HCl with 0.5% Triton X
! NaBH4 (1 mg/mL sterile
water), 3  5 minutes
PowerVisionþ Porcine SCs known
to be BrdU positive
Porcine SCs known
to be BrdU
positive
Antibodies Clone Dilution Source Preparation Methods Detection Systemb Positive Control Negative Control
Immunohistochemistry
BrdU Bu20a 1:20 Dako HIER with TEG-bufferf EnVisionþ None Section of different
porcine tissues
Abbreviations: ASMA, a-smooth muscle actin; BrdU, bromodeoxyuridine; HIER, heat-induced epitope retrieval þ TEG, Tris-EGTA buffer; NCAM, neural cell
adhesion molecule; SCs, satellite cells; SMCs, smooth-muscle cells.
aTBS, tris-buffered saline, pH 7.4.
bSecondary antibody was visualized using DABþ Chromogen (Dako, Denmark).
cPrimary antibody dilution was replaced with Dako REAL Antibody Diluent.
dNeoMarkers, ThermoScientific, Denmark.
eDako, Denmark.
fHIER with TEG: sections in TEG-buffer were heated in a microwave at 900 W for 15 minutes, followed by boiling at 440 W for 15 minutes and cooling for 15
minutes.
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Cells were counted using CAST 2.1.6.0 (Olympus) by
inserting systematic random counting frames in 5% of the cov-
erslip area.
Calculation and graphsweremade inGraphPadPrism, version
5.01. All estimates were expressed as mean+ standard error of
the mean.
Results
All pigs had a persistent fistula 4 weeks postoperative and at the
time of cell injection. One pig was excluded from the study at
the time of randomization due to insufficient weight gain, hence
4 pigs were assigned for injection of SCs/SMCs and 3 pigs
included in the control group. Sufficient weight gain was seen
in the remaining pigs, both in the treatment and control groups
(70.1+ 4.6 kg and 78.4+ 8.3 kg) with a small plateau in the
treatment group at the time of SCs/SMCs injection (Figure 1). In
the treatment group, One pig developed an incisional hernia due
to fast and extensive growth and was surgically treated. A sec-
ond pig developed a fistula between the bowel and the VVF, and
a third pig had a VVF located in the same level as cervix and
urethra. No animals died during the study period.
The isolated SC population consisted of 76.7% + 4.0%
NCAM-positive cells and SMC population of 88.6% + 4.1%
ASMA-positive cells (Figure 2A and B). However, SCs were
not able to differentiate in vitro (Figure 2D). Doubling times
for SCs and SMCs were 24.6 + 1.4 hours and 28.3 + 4.1
hours, respectively (Figure 3). With 98.8% + 0.6% BrdU-
positive cells prior to transplantation, nearly all cells were
BrdU labeled (Figure 2C).
After cell injection, 1 of the 4 VVFs was closed compared to
none in the control group (Figure 4). No histological differ-
ences in tissue composition between the 2 groups were detected
(Figure 5). Both groups showed signs of regeneration with
equal formation of collagen fibers and muscular tissue,
although distribution patterns appeared different (Figure 5).
We were able to detect the transition between vaginal stratified
squamous epithelium and bladder urothelium in all pigs in the
control group, indicating persistence of the VVF in all pigs
(Figure 6A). Presence of localized aggregates of multinucleated
giant cells was seen in the treatment group (Figure 6B). The
BrdU labeled, implanted cells could not be recovered.
Discussion
We have successfully created a reliable animal model with a
persisting VVF and proposed a method for cell implantation as
a possible treatment of VVF. One of the 4 VVFs was closed
after SCs/SMCs injection. No differences were seen in the
overall tissue composition between the 2 groups 5 weeks after
injection. No studies have evaluated the effect of stem cell
transplantation on VVF closure. The effect of stem cell trans-
plantation on fistula closure has primarily been examined in
small-scaled studies in patients with perianal fistulas due to
Crohn disease.18,19 We found an effect of SCs/SMCs in 1 of
the 4 treated pigs. However, our success rate is lower than the
effect of autologous adipose-derived stem cells (ASCs) or bone
marrow-derived mesenchymal stromal cells (MSCs) on peria-
nal fistula closure. Lee et al found an effect of autologous ASCs
in 82% (27 of 33) of patients18 and Ciccocioppo et al found an
effect of autologous MSCs in 58% (7 of 12) of patients.19 These
studies indicate an effect of stem cells on fistula closure in
settings with complex fistulas. The lower success rate of
SCs/SMCs in this study may be due to differences in fistula
type and stem cell source. The fistula between the bowel and
the VVF, which we discovered in 1 pig, could have affected the
healing process due to continuous leakage of intestinal fluid
through the VVF, hence maintaining the fistula. The location of
1 VVF at the same level as cervix and urethra in another pig
may also have affected the possibility of fistula closure. The
Figure 1. Weight gain in pigs in treatment group and control group
during the study period. Data shown as mean weight+ standard error
of the mean.
Figure 2. Immunocytochemical staining of satellite cells and smooth
muscle cells. Cells were positive for a-smooth muscle actin (A),
neural cell adhesion molecule (B), and bromodeoxyuridine (C) in
76.7%, 88.6%, and 98.8%, respectively. No desmin-positive myotubes
with more than 2 nuclei were observed after exposure of satellite cells
to proliferation medium for 7 days and differentiation medium for 17
days. A few myotube-like cells containing 2 to 3 nuclei were observed
(D; original magnification—A, B, D: 29, and C: 10).
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size of the persisting fistulas might also explain the low number
of closed fistulas. All remaining fistulas had a size over 10 mm
(data not shown), which is indicated to predict difficult fistula
closure.8 It would have been desirable to include more animals
in our study, given that the small number of animals could be
the reason why no effect was found.
Histological examinations showed that the injection of SCs/
SMCs and alginate gel did not induce formation of additional
connective tissue or muscular tissue. The role of SCs and SMCs
in fistula closure in the treatment group is therefore unknown.
It could be due to cell transplantation, bulking effect of the gel,
and induction of a reaction in the tissue or a combination of all.
One study found a bulking effect of a urethral submucosal
injection of hydrogel on stress urinary incontinence in a multi-
center study.20 To the extent of our knowledge no studies have
examined the effect of hydrogel or hydrogel in combination
with cells as a bulking agent on fistula closure. Spontaneous
closure cannot be excluded; however, this explanation is less
feasible since the remaining pigs all had persisting VVFs.
It is clear that some reaction against injected material hap-
pened. We found localized multinucleated giant cells in pigs
treated with injections containing SCs/SMCs and calcium
cross-linked alginate gel, indicating a chronic inflammatory
reaction. This is consistent with Chan et al who observed
increased activation of dendritic cells in vivo after an injection
of calcium cross-linked alginate gel compared to agarose gel,
collagen gel, and barium cross-linked alginate gel.21 Since we
used autologous cells, these results indicate that the formation
of multinucleated giant cells is related to the use of calcium as a
cross-linker mechanism. In future clinical studies one might
choose a less immunogenic material for cell delivery such as
human fibrin.
Cell Characteristic, Survival, and Migration
We characterized cells according to purity, growth kinetic, and
differentiation potential. Results indicate good purity levels.
Growth of fibroblast-like cells was seen in both the SC and the
SMC cultures (data not shown). Fibroblast in the cell culture
might have induced formation of connective tissue, which
would have induced fistula closure. With respect to the differ-
entiation potential of SCs Perruchot et al observed that SCs
Figure 3. Growth curve of satellite cells (SCs) and smooth muscle cells (SMCs). Cells were counted as triplicates after 24, 48, 72, 96, 120, and
144 hours. Doubling time for SCs and SMCs was 24.6 hours and 28.3 hours, respectively. Data shown as mean+ standard error of the mean.
Figure 4.Macroscopic illustration of a closed fistula (A) and a persisting fistula (B). One closed fistula was seen in the treatment group, while 3
persisted despite an injection of satellite cells and smooth muscle cells.
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from 6-week-old piglets were able to form myotube in vitro
with a fusion index of 65.3% after 4 days in DM.22 However,
we did not succeed in inducing differentiation of SCs using the
same protocol. Satellite cells in our study were isolated from
muscle tissue of 12-week-old pigs and the relatively older age
could be an explanation for why our SCs did not differentiate
in vitro. Zhu et al indicated that differentiation potential
declined with age, reporting a poor differentiation of SCs from
6- to 7-month-old pigs compared to 5- to 6-week-old piglets.23
Surviving transplanted cells were not found in the tissue
sections. We were not able to detect any BrdU-positive cells
at the time of evaluation. The lack of BrdU-positive cells may
be due to dilution of BrdU during cell division or low survival
rate of injected cells. One study reported detection of BrdU-
labeled ASCs 2 and 4 weeks after transplantation subcuta-
neously but not after 8 and 12 weeks.24 This could indicate
that long-term BrdU-detection after in vivo transplantation is
difficult. Since BrdU is diluted at each cell division, the pos-
sibility of detection depends on the cell growth kinetics. They
did not report the growth rate of their ASCs. We did not
evaluate the tissue structure and BrdU-labeling at an earlier
stage after injection. Therefore, we can neither exclude that
stem cells may have had an effect at earlier stages of regen-
eration nor determine whether the lack of BrdU-positive cells
is due to cell death or dilution. Detection of transplanted cells
could be improved by transfecting the cells with a green
Figure 5. Histological sections of fistula areas in the treatment group and the control group. HE staining (A-B) and Sirius red staining (C-D)
showing no differences in tissue structure between the 2 groups (original magnification: 0.5).
Abbreviation: HE, hematoxylin and erosin.
Figure 6. HE staining of fistula epithelia showing formation of a vesi-
covaginal fistula (A) andmultinucleated giant cells at the site of injection,
indicated by arrows (B; original magnification—A: 10 and B: 40).
Abbreviation: HE, hematoxylin and erosin.
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fluorescent protein (GFP) vector, which has been tried in
mice.25 However, there are no reports on stable GFP-
transfected porcine SCs.
The cell injection method may have affected cell survival
and migration as well as healing potential. The use of 2 separate
injection needles for stem cell suspension and calcium chlor-
ide, respectively, could have affected cell survival. An impre-
cise injection of calcium chloride increases the risk of
incomplete formation of hydrogel surrounding the cells,
thereby affecting cell survival. Cell survival and migration may
be increased by the use of a different material, for example, 3-
dimensional (3D) hydrogel scaffolds. Hill et al showed an
improved cell survival and migration with increasing pore size
in a 3D alginate scaffold.26 A scaffold, which is not liquid, may
have improved cell survival and migration, but may also be
more difficult to use for cystoscopic injections. Alternatively,
the injections could have been made both around and in the
fistula tract and in combination with scraping of the epithelium
to promote the healing process. The cell survival and migration
might also have been affected by the dynamic movement of the
bladder, which was tried to avoid by using continuous bladder
drainage after cell injection. This might not be as effective in
immobilizing the bladder as a catheter in humans.
Conclusion
We have established a reliable animal model with a persisting
clinical and histologically confirmed VVF in a simple surgical
procedure. We suggest a method for cell transplantation and
bulging, which can be used in future studies. Cystoscopic
guided injection of stem cells could be a possible treatment
of VVF in an outpatient setting with minimal patient discom-
fort, but has to be optimized further according to, for example,
formation of supporting gel, cell survival, and cell detection
methods.
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